# Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

> **NCT03993457** · PHASE4 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Bupropion

## Key facts

- **NCT ID:** NCT03993457
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-23
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** terminated during COVID due to inability to see participants in person.
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993457, "Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03993457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*